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Background: RAS (KRAS and NRAS) testing is required to predict anti-epidermal growth factor receptor (EGFR)
treatment efﬁcacy inmetastatic colorectal cancer (CRC). Although direct sequencing (DS)withmanualmicrodis-
section (MMD) is widely used, a diagnostic kit providing rapid detections of RASmutations would be clinically
beneﬁcial. We evaluated the MEBGENTM RASKET KIT (RASKET KIT), a multiplex assay using PCR-reverse se-
quence speciﬁc oligonucleotide and xMAP® technology to concurrently detect exon 2, 3, and 4 RAS mutations
in a short turnaround time (4.5 h/96-specimens).
Methods: Formalin-ﬁxed parafﬁn-embedded (FFPE) tissues were obtained from 308 consenting patients with
histologically-conﬁrmed CRC at six hospitals in Japan. For the RASKET KIT, we used only 50–100 ng DNA from
each FFPE specimen not processed by MMD. The primary endpoint was the concordance rate between RASmu-
tations identiﬁed with the RASKET KIT and two reference assays (DS with MMD and TheraScreen® K-RASMuta-
tion Kit). As the secondary endpoints,we evaluated the concordance rate betweenDS and the RASKET KIT for RAS
mutations in the wild-type KRAS exon 2 population and the genotyping performance of the RASKET KIT com-
pared with DS.
Findings: Among 307 analyzable specimens, the reference assays detected 140 (45.6%, 140/307) RASmutations:
111 KRAS exon 2 and 29 other (minor) RASmutations. The RASKETKIT detected 143 (46.6%, 143/307)mutations:
114KRAS exon 2 and 29minor RASmutations. The between-method concordance ratewas 96.7% (297/307) (95%
CI: 94.1–98.4%). Minor RASmutations were detected in 15.7% (30/191) of the wild-type KRAS exon 2 population
(n = 191); the concordance rate was 98.4% (188/191) (95% CI: 95.5–99.7%). The concordance rate of RAS
genotyping was 100% (139/139) (95% CI: 97–100%).
Interpretation: The RASKET KIT provides rapid and precise detections of RASmutations and consequently, quicker
and more effective anti-EGFR therapy for CRC (Study ID: UMIN000011784).
Funding:Medical & Biological Laboratories Co., Ltd. (MBL). MBL had roles in study design, data collection, data
analysis, and writing of the report for the study.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ment of Gastroenterology and
ital East, 6-5-1 Kashiwanoha,
. This is an open access article under1. Introduction
The clinical signiﬁcance of the detection of KRAS codon 12 and 13
mutations in patients with metastatic colorectal cancer (CRC) was
established from past randomized clinical trials, and then KRAS
mutation testing has been approved as compulsory testing before
anti-epidermal growth factor receptor (EGFR) antibody treatmentsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Lièvre et al., 2006; Van Cutsem et al., 2009). Recently, retrospective
RASmutation analyses of specimens fromphase II and III studies, includ-
ing panitumumab randomized trial in combination with chemotherapy
formetastatic colorectal cancer to determine efﬁcacy (PRIME) indicated
that similar to KRAS exon 2 mutations, KRAS exon 3 or 4, or NRAS exon
2, 3, or 4 mutation predicted non-response to add-on therapy with
panitumumab (Douillard et al., 2013; Heinemann et al., 2014;
Schwartzberg et al., 2014). Based on these results, assessment of all
RASmutational status in metastatic CRC patients prior to anti-EGFR an-
tibody therapy would be beneﬁcial for both patients' quality of life and
optimal use of healthcare resources; regulatory authorities and public
health institutions, such as the National Comprehensive Cancer Net-
work have recommended compulsory RAS testing (http://www.nccn.
org/professionals/physician_gls/pdf/colon.pdf). Indeed, the European
Medical Agency has published that the summary of product characteris-
tics for cetuximab and panitumumab has been revised to direct





According to several studies, hotspots of RASmutations have been
identiﬁed in codons 12, 13, 59, 61, 117, and 146, which are considered
to induce conformational changes into constitutively active forms(Prior et al., 2012; Smith et al., 2010). In addition, these genemutations
tend to occur in a mutually exclusive manner. These ﬁndings increase
the medical need for kits that can detect all RAS mutations occurring
in these codons. During the last decade, various techniques for RAS
testing (i.e., direct sequencing [DS], SURVEYOR®-WAVE method, pyro-
sequencing, allele-speciﬁc PCR, MALDI-TOF mass array, and BEAMing
[bead, emulsion, ampliﬁcation and magnetics] assay) have been devel-
oped (Diehl et al., 2008; Douillard et al., 2013; Heinemann et al., 2014;
Maughan et al., 2011; Parsons et al., 2011; Parsons and Myers, 2013).
Some of these methods require microdissected formalin-ﬁxed parafﬁn-
embedded (FFPE) tissues to enrich tumor cells for obtaining enough
amount of tumor-derived DNA. Although real-time PCR is one of the
common techniques for RAS testing, it requires a lot of wells and a
large amount of DNA to detect all RAS mutations. Next-generation
sequencing technologies are innovative, comprehensive and high
throughputmethods for RAS testing, which are larger-sized for RAS test-
ing in the present clinical practice. On the other hand, Luminex®-
xMAP® technology can provide multiplex molecular testing in a sin-
gle well, and only requires a small amount of tumor-derived DNA, as
previously reported (Bando et al., 2013; Fukushima et al., 2011), so
that the MEBGENTM RASKET KIT (RASKET KIT) could be considered
as more cost-effective for RAS testing. In this study, we evaluated
the RASKET KIT to detect forty-eight kinds of RAS amino acid muta-
tions in CRC patients. This study is also performed as a registration
trial for regulatory approval.2. Methods
2.1. Patients
Eligibility criteria for patients were 1) patients aged≥20 years, 2) histologically conﬁrmed adenocarcinoma of colorectal origin, 3) availability of
adequate amount of FFPE tissues, and 4) provided patients' written consent for participation in the study, between September and November 2013.
The study was approved by the institutional review boards of all of six hospitals and performed in accordance with the Declaration of Helsinki and
ethical guidelines for clinical research.
2.2. Study Design
The study was performed in the patients satisfying the criteria. All of the sample specimens were anonymized in a manner which only the six
hospitals were able to connect to patients' personal information using a correspondence table, which was strictly controlled at each study site to
avoid any disclosure to outsiders.
We sent the same anonymized FFPE sample set to three reference laboratories (G&G Science Co., Ltd., LSI Medience Corporation, and SRL Inc.)
which independently generated data by one of RASKET KIT, DS, and TheraScreen® K-RAS Mutation Kit (TheraScreen Kit), respectively. Each labora-
tory performed RAS testing in blinded. The primary endpoint of the study was the concordance rate between results obtained with the RASKET KIT
and the two reference assays, DS with manual microdissection (MMD) and TheraScreen Kit (for KRAS exon 2 mutation analysis only), in identifying
RAS (KRAS andNRAS) exon 2, 3, and 4mutations. For KRAS gene exon 2, a specimenwas deﬁned as amutation-positive result if a mutation in codons
12 and 13 was detected by at least either one of the two reference assays. The patients conﬁrmed as wild-type (WT) KRAS exon 2 were allocated for
the secondary endpoint-1 analysis— the concordance rate between DS and RASKET KIT forminor RAS (KRAS exons 3 and 4, andNRAS exons 2, 3, and
4) mutations. All the patient samples conﬁrmed as RASmutation positive were then proceeded to the analysis for secondary endpoint-2 analysis —
accuracy of RASmutation genotyping through the RASKET KIT.
2.3. Histopathologic Evaluation of Specimens
Wepreparedhematoxylin– and eosin (HE)-stained slides using 2 μm-thick FFPE sections. Onepathologist assigned for the studymicroscopically con-
ﬁrmed cancer in each patient, calculated the tumor area ratio and tumor cell ratio, andmarked tumor area on the prepared HE-stained slides for MMD.
2.4. Direct Sequencing
We used 10 μm-thick FFPE serial sections for DNA extraction. After the pathological conﬁrmation of cancer in each patient, the 10 μm-thick sec-
tionswere then processed byMMD to avoid a possible case that the sensitivity is too low to adequately detect RASmutations (Domagała et al., 2012).
DNA extraction was performed with QIAamp® DNA FFPE Tissue Kit (Qiagen, Venlo, Netherlands) according to the manufacturer's protocol. Brieﬂy,
each extracted DNA was ampliﬁed using six sets of primers to amplify exon 2, exon 3, and exon 4 in KRAS and NRAS (Table S1). RAS exon 2, 3, and
4mutationswere detected using the BigDye® Terminator Cycle Sequencing kit (Thermo Fisher Scientiﬁc,MA, USA) and analyzed on a 3130xl Genetic
Analyzer (Thermo Fisher Scientiﬁc).
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The DNA extraction from the 10 μm-thick sections was performed with QIAamp DNA FFPE Tissue Kit according to the manufacturer's protocol.
Then, real-time PCR was performed to detect seven types of mutations in codons 12 and 13 of KRAS exon 2 (i.e., G12S, G12C, G12R, G12D, G12V,
G12A, and G13D) using TheraScreen Kit (Qiagen) according to the manufacturer's instruction.
2.6. Assay with MEBGENTM RASKET KIT
DNA extraction was performed using a modiﬁed protocol as described previously (Fukushima et al., 2011; Gilbert et al., 2007). Each extracted
DNA sample was diluted to a concentration of 10–20 ng/μL with sterile TE buffer (1 mmol/L Tris–HCl [pH = 8.0], 0.1 mmol/L EDTA). Assay with
RASKET KIT (MBL, Nagoya, Japan) was performed as the manufacturer's protocol. The ampliﬁcation was performed in a ﬁnal volume of 25 μL
[20 μL master mix, including primers, Taq DNA polymerase, and Uracil-DNA-glycosylase (UDG), and 5 μL extracted DNA]. Reactions were heated
for 5 min at 40 °C and 2 min at 95 °C; 10 repeating cycles of 94 °C for 20 s and 62 °C for 30 s; 45 repeating cycles of 90 °C for 20 s, 60 °C for 30 s,
and 72 °C for 30 s; and then 72 °C for 1 min and 94 °C for 10 min. Each ampliﬁcation product was then hybridized to mutation detection probes
immobilized with color-coded beads. 5 μL of PCR products and 45 μL of hybridization solution containing probe-coupled beads were hybridized at
95 °C for 2 min followed by 55 °C for 30 min. After washing, the PCR ampliﬁcation-bead complexes were reacted with streptavidin–phycoerythrin
(SA–PE) at 52 °C for 15 min. Using Luminex® 100/200TM (Luminex, TX, USA), we counted median ﬂuorescence intensity (MFI) for the color-coded
beads and PE, representing types of RAS mutations and their signal intensities, respectively. UniMAGTM (data analysis software, MBL) was then
used for analyzing raw data from Luminex® 100/200TM. Thus, using RASKET KIT, we examined twelve types of RAS exon 2 (G12S, G12C, G12R,
G12D, G12V, G12A, G13S, G13C, G13R, G13D, G13V, and G13A), eight types of RAS exon 3 (A59T, A59G, Q61K, Q61E, Q61L, Q61P, Q61R, and
Q61H), and four types of RAS exon 4 (K117N, A146T, A146P, and A146V) mutations, simultaneously (Table S2).
The evaluation criterion for the RASKET KIT was ≥90% of concordance rate with the reference assays in the primary and secondary endpoint
analysis-1. In case of any controversial data between RASKET KIT and the reference assays, we conﬁrmed the results with TaqMan®Mutation Detec-
tion Assays (Thermo Fisher Scientiﬁc) (Didelot et al., 2012).
2.7. Statistical Analysis
The number of specimens required for the study was estimated as the number of specimens to satisfy that the rate of concordance between the
RASKETKIT and the reference assayswould beN90% at the lower limit of the 95% conﬁdence interval (CI). Thenwe determined the number should be
N278, using the following equation:
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FFPE tissues were obtained from 309 consenting patients with
histologically-conﬁrmed CRC at the six hospitals (50–55 samples per
hospital) (Fig. 1). Sufﬁcient FFPE tissues were not available in one pa-
tient, and data from one reference assay was not reportable; therefore
307 samples were included in the primary endpoint analysis. Among
them, 191 patient (62.2%, 191/307) samples were conﬁrmed as WT
KRAS exon 2 and were then proceeded to the secondary endpoint-1
analysis. Also, 138 patient sampleswere conﬁrmed asmutation positive
by both the RASKET KIT and DS and were included in the secondary
endpoint analysis-2.3.2. Assay Success Rates
The overall assay success rates for the three RAS genetic assays
(RASKET KIT, DS, and TheraScreen Kit) used in this study are shown in
Table S3. In all the assays, the success rates were no less than 99%.
Two samples were indeterminate with the RASKET KIT, which had pos-
itive and negative results with the reference assays. The former resulted
in PCR ampliﬁcation failure at NRAS exon 4 region, even detected KRAS
exon 2 mutation with the RASKET KIT. The latter had PCR ampliﬁcation
failure at multiple exons (KRAS exon 2, exon 3, and exon 4; and NRAS
exon 4), and no RAS mutations were detected from the other exons
with the RASKET KIT.3.3. Frequency of RAS Mutations
Among the 307 specimens assayed, the RASKET KIT detected 143
(46.6%, 143/307) mutations: 114 KRAS exon 2 and 29 minor RAS
mutations. The reference assays detected 140 (45.6%, 140/307) RAS
mutations: 111 KRAS exon 2 and 29 minor RASmutations. The popula-
tion with RAS mutations detected by either one of the methods was
146 (47.6%, 146/307). The frequencies of mutations in exons 2, 3, and
4 were 37.8% (116/307), 2.0% (6/307) and 3.3% (10/307) in KRAS, and
2.0% (6/307), 2.6% (8/307), and 0% (0/307) in NRAS, respectively. Nota-
bly, among the 191 specimens conﬁrmed as WT KRAS exon 2, the fre-
quency of minor RASmutations was 15.7% (30/191) (Table 1).
3.4. Between-kit RAS Status Concordance (Primary Endpoint Analysis)
The concordance rate between results obtained with RASKET KIT
and the reference assays in assessing KRAS and NRAS exon 2, 3, and 4
mutations was 96.7% (297/307) (95% CI: 94.1–98.4%). The agreement
in detecting positive RAS mutations was 97.9% (137/140) (95% CI:
93.9–99.6%), while that for detecting negative mutations was 95.8%
(160/167) (95% CI: 91.6–98.3%) (Table 2a).
On the other hand, there were several samples with conﬂicting re-
sults between the RASKET KIT and the reference assays. Six samples of
them were including one specimen with KRAS G12R, two with KRAS
G12D, two with KRAS G13D, and one with KRAS Q61H detected by the
RASKET KIT, but all the samples were negative with both the reference
assays. We conﬁrmed these samples using TaqManMutation Detection
Assays, which is capable of detectingmutations in a sample at a level of
Tumor FFPE specimens (n=308)
Results of reference assays
Full analysis set
 (307 specimens reported reference assay data)
Results of RASKET KIT
Sufficient amount of FFPE specimen not available (n=1)
CRC patients (n=309) 
MEBGEN RASKET KIT 
Without RAS mutation (n=163) 
 With RAS mutation (n=143) 
RAS mutation and PCR failure 
in some exons (n=1) 
PCR failure (n=1)
Direct Sequencing 
Without RAS mutation (n=167) 
 With RAS mutation (n=140) 
   PCR failure (n=1)
TheraScreen K-RAS kit 
Without RAS mutation (n=198) 
 With RAS mutation (n=108) 
   PCR failure (n=2)
Specimen failed with reference assays (n=1) 
[Without RAS mutation in RASKET KIT]
Assessable for all RAS mutations (n=307) [primary endpoint analysis] 
With KRAS exon 2 mutations 
(n=116) 
Without RAS mutations by both 
RASKET KIT and DS methods 
(n=169) 
Assessable for minor RAS mutations (n=191) 
[secondary endpoint analysis-1] 
Assessable for accuracy of RAS mutation 
genotyping (n=138) 
[secondary endpoint analysis-2] 
Fig. 1. Study design and patients eligible for primary and secondary endpoint analyses.
Among 307 assessable samples, 191 samples having RASmutations other than those in exon 2 were forwarded to secondary endpoint analysis-1. Also, 138 samples with RASmutation
resulted by at least one assay were included to secondary endpoint analysis-2.
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tion positive (Table 3). The other two conﬂicting samples were shown
asmutation negative with the RASKET KIT and positive by the DSmeth-
od. One sample had a mutation in KRAS codon 11 as well as KRAS G12C.
KRAS codon 11 is located in the region of mutation detection probes
immobilized KRAS exon 2 color-coded beads, so that the PCR ampliﬁca-
tion product with the codon 11 mutation did not bind even to G12C
beads. The other sample was a KRAS exon 3 mutation (A59E), which is
a mutation outside the detectable range of the RASKET KIT.3.5. Between-kit RAS Status Concordance in WT KRAS Exon 2 Population
(Secondary Endpoint Analysis-1)
A total of 191 patients were conﬁrmed asWT KRAS exon 2 and were
included in the secondary endpoint analysis-1. The concordance rate
between RASKET KIT and DS for secondary endpoint analysis-1 was
98.4% (188/191) (95% CI, 95.5–99.7%) (Table 2b).3.6. Accuracy of RAS Mutation Genotyping (Secondary Endpoint
Analysis-2)
Specimens conﬁrmed as mutation positive by both the RASKET KIT
and DS were included in the analysis of secondary endpoint analysis-
2. The concordance of each genotype for the overall population as
assessed by the RASKET KIT and DS was 100% (139/139) (95% CI, 97%–
100%) (Table 4).
4. Discussion
This study is the ﬁrst to demonstrate a clinical usefulness of RASKET
KIT, a CE-marked and approved by the Ministry of Health, Labour and
Welfare of Japan in vitro diagnostics (IVD) kit for determination of all
RAS mutation status in FFPE tissues of CRC patients. For the purpose,
we prospectively compared the RASKET KIT to TheraScreen Kit and DS
with MMD which are the gold standard for RAS testing (Massarelli
et al., 2007). Our data revealed that the overall concordance rate
Table 1
Frequency of all RASmutations detected in colorectal cancer patients.
RAS status No. of cases Proportion among 307 cases
WT RAS 162 52.8%







p.G12R, p.G12A 1 0.3%
p.G13C 1 0.3%
p.G13D 20 6.5%
p.G12D, p.G13D 2 0.7%
Other KRAS exon 2 mutanta 0 0%
KRAS exon 3 mutant 6 2.0%
p.A59E 1 0.3%
p.Q61H 5 1.6%
Other KRAS exon 3 mutantb 0 0%





NRAS exon 2 mutant 6 2.0%
p.G12D 4 1.3%
p.G12V 2 0.7%
Other NRAS exon 2 mutantc 0 0%




Other NRAS exon 3 mutantd 0 0%
NRAS exon 4 mutante 0 0%
Prevalence of each RASmutation presented as n and %.
a KRAS p.G13S, p.G13R, p.G13V, and p.G13A.
b KRAS p.A59T, p.A59G, p.Q61K, p.Q61E, p.Q61L, p.Q61P, and p.Q61R.
c NRAS p.G12S, pG12C, p.G12R, and p.G12A.
d NRAS p.A59T, p.A59G, pQ61E, p.Q61P, and Q61H.
e NRAS p.K117N, p.A146T, p.A146P, and p.A146V.
Table 2b
Secondary endpoint analysis-1/concordance of mutations detected with RASKET KIT ver-
sus direct sequencing in KRAS exon 2 mutation-negative patients (n= 191).







MEBGEN RASKET KIT Mutation positive 28 1 29
Mutation negative 1 160 161
Not reportable 0 1 1
Total 29 162 191
Overall percent agreement 98.4% (95% CI, 95.5%–99.7%)
Positive percent agreement 96.6% (95% CI, 82.2%–99.9%)
Negative percent agreement 98.8% (95% CI, 95.6%–99.9%)
Results of concordance rate inKRAS exon3, and exon 4, andNRAS exon 2, exon 3, and exon
4. Data are number of samples and percentage. Each percent agreement is calculatedwith
the numbers.
321T. Yoshino et al. / EBioMedicine 2 (2015) 317–323(96.7%, 297/307) was satisﬁed with the predeﬁned criterion (N90%). As
a useful kit detecting all RASmutations, the capability of detectingminor
RAS mutations other than KRAS exon 2 is required. Our study also
showed a high concordance rate of 98.4% (188/191) betweenmutation-
al status obtained with the RASKET KIT and DS with MMD, in WT KRAS
exon 2 population (n = 191). Similar to the overall concordance rate,
the positive and negative concordance rates were no less than 95%.
The frequency of RAS mutations detected with the RASKET KIT in our
study agreed with those reported in the several past studies
(Bokemeyer et al., 2009; Douillard et al., 2010, 2013; Heinemann
et al., 2014; Watanabe et al., 2013). For example, 37.1% (114/307) inTable 2a
Primary endpoint analysis/concordance of mutations detected with RASKET KIT versus







MEBGEN RASKET KIT Mutation positive 137 6 143
Mutation negative 2 160 162
Not reportable 1 1 2
Total 140 167 307
Overall percent agreement 96.7% (95% CI, 94.1%–98.4%)
Positive percent agreement 97.9% (95% CI, 93.9%–99.6%)
Negative percent agreement 95.8% (95% CI, 91.6%–98.3%)
Results of concordance rate inKRAS andNRAS exon 2, exon 3, and exon 4. Data are number
of samples and percentage. Each percent agreement is calculated with the numbers.exon 2 detected in this study corresponded with the 37.6% reported in
a large-scaled Japanese study (Watanabe et al., 2013).
KRAS testing to determine exon 2 status prior to anti-EGFR treat-
ment for CRC patients has been widely used (Normanno et al., 2009).
Many KRAS exon 2 mutation detection kits such as TheraScreen Kit are
approved as IVD in Japan, USA, and Europe. Recent studies suggested
that additional RASmutation aswell as KRAS exon 2 could predict an ef-
ﬁcacy of anti-EGFR treatment, and consequently the indication of anti-
EGFR therapeutic antibodies has been revised to direct the treatment
of patients with wild-type RAS (both KRAS and NRAS) metastatic CRC
(Douillard et al., 2013; Heinemann et al., 2014; Schwartzberg et al.,
2014). Thus, expanded RAS testing using an approved IVD kit is
recommended.
We had several inconsistent results between theRASKETKIT and the
reference assays. Six specimens were determined as positive with
RASKET KIT and negative with the reference assays. According to the
conﬁrmation study using TaqMan Mutation Detection Assays, all of
the six specimens were RASmutation positive. Such discrepancy may
be caused by a smaller amount of mutant DNA. Indeed, as shown in
Table 3, the ratios of mutant RAS DNA to WT RAS DNA were 0.1–1% in
two specimens and 1–5% in three out of the six specimens. Another con-
ﬂicting data was found in a sample with over 5% of mutant RAS DNA. In
this study, although FFPE sections were equally distributed to three ref-
erence laboratories, it could not be completely denied a possibility of
intratumoral heterogeneity. Bando et al. reported that the results by
TheraScreen Kit whose sensitivity seems to be 1–5% were correlated
with anti-EGFR therapeutic efﬁcacy more than those by DS (Bando
et al., 2011). On the other hand, a recent data suggested that patients
with low-frequency (b1%) KRAS mutations may beneﬁt of targeted
anti-EGFR therapies (Laurent-Puig et al., 2014). The detection sensitivi-
ty of the RASKET KIT would also be at least 1–5%, which means that theTable 3
Discrepancy samples between RASKET KIT and reference assays conﬁrmed by TaqMan
Mutation Detection Assays.
RASKET KIT Reference assays Percentage of mutant DNA in
TaqMan Mutation Detection Assays
KRAS p.G12D WT 2.8% (p.G12D)
KRAS p.G12D WT 1.8% (p.G12D)
KRAS p.G12R WT 0.3% (p.G12R)
KRAS p.G13D WT 0.4% (p.G13D)
KRAS p.G13D WT 2.0% (p.G13D)
KRAS p.Q61H WT 38.9% (p.Q61H)
WT KRAS p.G12Ca Not tested
WT KRAS p.A59E Not tested
Eight samples are in conﬂicting between MEBGEN RAKET KIT and reference assays. Data
are shown as each result of those assays and percentage of amount of mutated DNA
among total sample.
a KRAS p.A11A (c.33TNC) and KRAS p.G12C (c.34GNT) positive.
Table 4
Secondary endpoint analysis-2/genotyping performance of the RASKET KIT and direct sequencing.
Direct sequencing
KRAS NRAS
G12S G12C G12R G12D G12V G12A G13C G13D Q61H K117N A146T A146P A146V G12D G12V Q61K Q61L Q61R


















All of mutational data obtained by MEBGEN RASKET KIT was identical to those done by direct sequencing.
322 T. Yoshino et al. / EBioMedicine 2 (2015) 317–323detection of each RASmutation can be thoroughly secured in samples
with 5% RASmutant allele in wild-type RAS genes and some of those al-
leles could be detected even in case of 1% (Table S4a and S4b). Thus, this
kit can provide clinically appropriate detection of RAS mutations, al-
though not being able to quantify the mutations can be a limitation in
using this kit to screen the KRASmutations for metastatic CRC patients.
Further investigation will be needed to clarify the most appropriate
detection sensitivity of RASmutation as a companion diagnostics prior
to anti-EGFR therapies.
The RASKET KIT is designed to detect a total of forty-eight RAS amino
acid mutations in codons 12, 13, 59, 61, 117, and 146. These codons are
recognized as mutational hotspots for RAS genes (Prior et al., 2012;
Smith et al., 2010). In this study, there were two false negative results
in the RASKET KIT, not caused by a lower DNA amount. One was the
sample with KRAS A59E mutation, which is not included in the
RASKET KIT, due to a rare mutation. Indeed, this mutation was not re-
ported in the PRIME study, but A59E was not at all (Douillard et al.,
2010). The other false negative sample had double mutations in KRAS
codon 11 and codon 12 (G12C). The codon 11 region is located at the
next to codons 12 and 13, so that the probes for detecting codons 12
and 13 mutations also include the sequence for codon 11. Based on
the assay principle, PCR ampliﬁcations including codon 11 mutation
would not be able to hybridize to any detection beads for codons 12
and 13. Anyway, according to past reports, these results would have lit-
tle impact on clinical performance of the RASKET KIT so far, as both
cases would hardly occur in clinical practice (Amado et al., 2008;
Bokemeyer et al., 2009; Douillard et al., 2010; Heinemann et al., 2014;
Schwartzberg et al., 2014).
Luminex®-xMAP® technology has been widely applied for not only
protein assays, but also several multiplex molecular testings, such as
HLA genotyping and virus genotyping, which require differential detec-
tions from a number of related sequencing (Itoh et al., 2005; Ozaki et al.,
2014). Hence, this technique could be suitable for molecular testing for
personalized cancer medicine. Indeed, several studies previously re-
ported usefulness of assay kits using this technique (Bando et al.,
2013; Kawamoto et al., 2012; Shinozaki et al., 2014). For example,
GENOSEARCHTM Mu-PACK detects mutations in BRAF (V600K and,
V600E) and PIK3CA (E542K, E545K, Q546K, H1047R, and H1047L) as
well as some regions of RAS (Bando et al., 2013). This kit would also
be expected to be approved as an IVD kit. In the point of view of such
multiplex molecular assay, any possible cross reactions should be
avoided for appropriate assays. Actually, the RASKET KIT offers a PCRreaction of eight regions simultaneously, in a singlewell. For performing
RAS testing by DS, it is required to visually conﬁrm to distinguish a sig-
niﬁcant peak and a noise on chromatogram. The RASKET KIT can pro-
vide us an objective detection of RASmutation using cut-off values in
a short turnaround time (approximately 4.5 h) and regardless of the
number of samples less than 96. This speciﬁcation may be a beneﬁt for
pathological laboratories of any size, especially centralized reference
laboratories. Physicians struggle to clinically diagnosis for starting
early treatments for any diseases, so that RAS mutation detections by
the RASKET KIT would be beneﬁcial for CRC patients, as well. Further-
more, the amount of DNA required for detection of all RASmutation is
quite a few (50–100 ng/48 mutations/well) in the RASKET KIT, unlike
other techniques which perform reactions as one mutation/well. Even
for expansion of testing from KRAS to all RAS, RASKET KIT could require
the same amount of DNA and consequently keep the same testing cost
as well. Thus, the RASKET KIT is well-designed for rapid, high through-
put and multiplex detection of all RASmutations.
In conclusion, the clinical evaluation study of the MEBGENTM
RASKET KIT met the predeﬁned primary and secondary endpoints and
showed a high concordance ratewith existing RAS or KRASmutation as-
says. The RASKET KIT provides rapid and precise detection of RASmuta-
tions from FFPE CRC tissue, allowing oncologists to more quickly and
effectively target treatment to individual patients.
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